SCHEMBL13098733

SCHEMBL13098733

CC1(C)OB(c2cccc3c(O)cccc23)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.39
BTK Q06187 1/20 0.39
LPL P06858 7/20 0.37
LIPG Q9Y5X9 7/20 0.37
IDO1 P14902 2/20 0.37
CYP1A2 P05177 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
APP P05067 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
SNCA P37840 1/20 0.36
RECQL P46063 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA1 P00915 4/20 0.35
CA2 P00918 4/20 0.35
CA9 Q16790 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479006 1.00 JAK2 (0.39) JAK2BTKLPLLIPGIDO1
SCHEMBL29388148 0.89 IDO1 (0.46) JAK2BTKLPLLIPGIDO1
SCHEMBL15586496 0.89 IDO1 (0.46) JAK2BTKLPLLIPGIDO1
SCHEMBL13527502 0.89 LPL (0.44) JAK2BTKLPLLIPGCA1
SCHEMBL31170540 0.81 JAK2 (0.35) JAK2BTKLPLLIPGCYP1A2
SCHEMBL333869 0.81 LPL (0.46) JAK2BTKLPLLIPGHPGD
SCHEMBL2027186 0.81 LPL (0.48) JAK2BTKLPLLIPGCA1
SCHEMBL3203922 0.80 JAK2 (0.42) JAK2BTKLPLLIPGCA1
SCHEMBL15073956 0.80 LPL (0.38) JAK2BTKLPLLIPG
SCHEMBL17322311 0.80 CYP1A2 (0.48) JAK2BTKLPLLIPGCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 US disclosed
US-8957407-B2 Anthracene derivatives, preparation method thereof and organic light emitting diode using the same LG CHEM, LTD. (KR) 2015-02-17 US disclosed
US-8957407-B2 Anthracene derivatives, preparation method thereof and organic light emitting diode using the same LG CHEM, LTD. (KR) 2015-02-17 US disclosed
US-20100252817-A1 New Anthracene Derivatives, Preparation Method Thereof and Organic Light Emitting Diode Using the Same LG CHEM. LTD. (KR) 2010-10-07 US disclosed
US-20100252817-A1 New Anthracene Derivatives, Preparation Method Thereof and Organic Light Emitting Diode Using the Same LG CHEM. LTD. (KR) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100252817-A1 New Anthracene Derivatives, Preparation Method Thereof and Organic Light Emitting Diode Using the Same CYBA, XPOT, TOMM22 JAK2 2532/4885BTK 1809/4885LPL 3685/4885
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC JAK2 1651/4885BTK 3193/4885LPL 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.